Prostate-Specific Antigen

News Prostate-Specific Antigen

• Intermittent hormone therapy for prostate cancer inferior to continuous therapy

  An international randomized study finds intermittent androgen-deprivation therapy has some quality-of-life benefits, but overall survival times don’t measure up to those seen with continuous therapy.Many men with metastatic, hormone-sensitive prostate cancer live longer on continuous androgen-depriv more

• Alpharadin Significantly Improves Overall Survival for Patients with Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases

  Algeta ASA announced results from the phase III ALSYMPCA study with the investigational agent Alpharadin (radium-223 chloride). The study met its primary endpoint by significantly improving survival by 44% [hazard ratio (HR)=0.695; p=0.00185] in patients with castration-resistant (hormone-refractory more

• Urine test shows prostate cancer risk, U-M study finds

  A new urine test can help aid early detection of and treatment decisions about prostate cancer, a study from the University of Michigan Comprehensive Cancer Center and the Michigan Center for Translational Pathology finds. The test supplements an elevated prostate specific antigen, or PSA, screening more

Publications Prostate-Specific Antigen

• Development of a label‐free LC‐MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical tri ...

  Prostate cancer is one of the leading causes of male mortality in the Western world. Currently, radiation combined with hormone treatment is one of the principle curative regimes for localised disease. Significantly, of the patients treated this way approximately 25% subsequently experience diseas more

• CHD1 Is a 5q21 Tumor Suppressor Required for ERG Rearrangement in Prostate Cancer

  Deletions involving the chromosomal band 5q21 are among the most frequent alterations in prostate cancer. Using single-nucleotide polymorphism (SNP) arrays, we mapped a 1.3 megabase minimally deleted region including only the repulsive guidance molecule B (RGMB) and chromodomain helicase DNA-binding more

• An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer

  Androgen deprivation therapy remains the mainstay of medical treatment for advanced prostate cancer. Commonly, this is achieved with medical androgen deprivation rather than surgical intervention as the permanence and psychological effects of the latter are unacceptable for most patients. Degarelix more

Market studies Prostate-Specific Antigen

• Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology

  GBI Research, the leading business intelligence provider, has released its latest research “Clinical Trial Endpoints in Oncology – Inclusion of Surrogate Endpoints and Shorter Endpoints will Ensure Faster Clinical Trials in Oncology”, which essentially provides insights into clinical trial endpoints more

Websites Prostate-Specific Antigen